Abrus agglutinin is a potent anti-proliferative and anti-Angiogenic agent in human breast cancer

International Journal of Cancer

Volumn 139, Issue 2, 2016, Pages 457-466

  Bhutia, Sujit K ^a   Behera, Birendra ^b   Nandini Das, Durgesh ^a   Mukhopadhyay, Subhadip ^a   Sinha, Niharika ^a   Panda, Prashanta Kumar ^a   Naik, Prajna Paramita ^a   Patra, Samir K ^a   Mandal, Mahitosh ^b   Sarkar, Siddik ^c   Menezes, Mitchell E ^c   Talukdar, Sarmistha ^c   Maiti, Tapas K ^b   Das, Swadesh K ^c   Sarkar, Devanand ^c,d   Fisher, Paul B ^c,d  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY   (India)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Abrus; Akt; angiogenesis; apoptosis; IGFBP 2; ROS

Indexed keywords

CD31 ANTIGEN; KI 67 ANTIGEN; PLANT LECTIN; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN BINDING PROTEIN 2; ABRUS AGGLUTININ; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT;

ABRUS; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BREAST TUMOR; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLANT LECTINS; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962640230     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30055     Document Type: Article

References (48)

1. Hanahan D, Weinberg RA., Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
2. Bhutia SK, Mallick SK, Maiti TK., Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int 2010; 34: 553-63.
3. Fu LL, Zhou CC, Yao S, et al., Plant lectins: targeting programmed cell death pathways as antitumor agents. Int J Biochem Cell Biol 2011; 43: 1442-9.
4. Liu B, Bian HJ, Bao JK., Plant lectins: potential antineoplastic drugs from bench to clinic. Cancer Lett 2010; 287: 1-2.
5. De Mejía EG, Prisecaru VI., Lectins as bioactive plant proteins: a potential in cancer treatment. Crit Rev Food Sci Nutr 2005; 45: 425-45.
6. Goldstein IJ, Hughes RC, Monsigny M, et al., What should be called a lectin? Nature 1980; 285: 66.
7. Rüdiger H, Gabius HJ., Plant lectins: occurrence, biochemistry, functions and applications. Glycoconj J 2001; 18: 589-613.
8. Hoessli DC, Ahmad I., Mistletoe lectins: carbohydrate-specific apoptosis inducers and immunomodulators. Curr Org Chem 2008; 12: 918-25.
9. Li WW, Yu JY, Xu HL, et al., Concanavalin A: a potential anti-neoplastic agent targeting apoptosis, autophagy and anti-Angiogenesis for cancer therapeutics. Biochem Biophys Res Commun 2011; 414: 282-6.
10. Bhutia SK, Maiti TK,. Crabs eye (Abrus precatorius) seed and its immunomodulatory and antitumor properties. In:, Preedy VR, Watson RR, Patel VB, eds. Nuts and seeds in Health and Disease Prevention. Academic Press, Elsevier 2011, Chapt 49: 409-15. DOI: 10.1016/B978-0-12-375688-6.10049-0
11. Hegde R, Maiti TK, Podder SK., Purification and characterization of three toxins and two agglutinins from Abrus precatorius seed by using lactamyl-Sepharose affinity chromatography. Anal Biochem 1991; 194: 101-9.
12. Bagaria A, Surendranath K, Ramagopal UA, et al., Structure-function analysis and insights into the reduced toxicity of Abrus precatorius agglutinin I in relation to abrin. J Biol Chem 2006; 281: 34465-74.
13. Reddy VV, Sirsi M., Effect of Abrus precatorius L. on experimental tumors. Cancer Res 1969; 29: 1447-51.
14. Ghosh D, Maiti TK., Immunomodulatory and antitumor activities of native and heat denatured Abrus agglutinin. Immunobiology 2007; 212: 589-99.
15. Ghosh D, Maiti TK., Effects of native and heat-denatured Abrus agglutinin on tumor-Associated macrophages in Dalton's lymphoma mice. Immunobiology 2007; 212: 667-73.
16. Ghosh D, Bhutia SK, Mallick SK, et al., Stimulation of murine B and T lymphocytes by native and heat-denatured Abrus agglutinin. Immunobiology 2009; 214: 227-34.
17. Tripathi S, Maiti TK., Efficiency of heat denatured lectins from Abrus precatorius as immunoadjuvants. Food Agric Immunol 2003; 15: 279-87.
18. Tripathi S, Maiti TK., Stimulation of murine macrophages by native and heat-denatured lectin from Abrus precatorius. Int Immunopharmacol 2003; 3: 375-81.
19. Tripathi S, Maiti TK., Immunomodulatory role of native and heat denatured agglutinin from Abrus precatorius. Int J Biochem Cell Biol 2005; 37: 451-62.
20. Bhutia SK, Mallick SK, Stevens SM, et al., Induction of mitochondria-dependent apoptosis by Abrus agglutinin derived peptides in human cervical cancer cell. Toxicol In Vitro 2008; 22: 344-51.
21. Bhutia SK, Mallick SK, Maiti S, et al., Antitumor and proapoptotic effect of Abrus agglutinin derived peptide in Dalton's lymphoma tumor model. Chem Biol Interact 2008; 174: 11-8.
22. Bhutia SK, Mallick SK, Maiti TK., In vitro immunostimulatory properties of Abrus lectins derived peptides in tumor bearing mice. Phytomed 2009; 16: 776-82.
23. Bhutia SK, Das SK, Kegelman TP, et al., mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol 2012; 227: 1805-13.
24. Das SK, Bhutia SK, Azab B, et al., MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Res 2013; 73: 844-54.
25. Yance DR, Jr, Sagar SM., Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther 2006; 5: 9-29.
26. Fidler IJ, Ellis LM., The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
27. Seifert G, Jesse P, Laengler A, et al., Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 2008; 264: 218-28.
28. Wood DE, Thomas A, Devi LA, et al., Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 1998; 17: 1069-78.
29. Gao G, Dou QP., N-terminal cleavage of Bax by calpain generates a potent proapoptotic 18-kDa fragment that promotes bcl-2-independent cytochrome C release and apoptotic cell death. J Cell Biochem 2000; 80: 53-72.
30. Liu B, Zhang B, Min MW, et al., Induction of apoptosis by Polygonatum odoratum lectin and its molecular mechanisms in murine fibrosarcoma L929 cells. Biochim Biophys Acta 2009; 1790: 840-4.
31. Simon HU, Haj-Yehia A, Levi-Schaffer F., Role of reactive oxygen species in apoptosis induction. Apoptosis 2000; 5: 415-8.
32. Kang KS, Wang P, Yamabe N, et al., Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS One 2010; 5: e10296.
33. Morrison BW, Doudican NA, Patel KR, et al., Disulfiram induces copper-dependent stimulation of reactive oxygen species and activation of the extrinsic apoptotic pathway in melanoma. Melanoma Res 2010; 20: 11-20.
34. Vivanco I, Sawyers CL., The phosphatidylinositol 3-kinaseAKT pathway inhuman cancer. Nat Rev Cancer 2002; 2: 489-501.
35. Plas DR, Thompson CB., Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005; 24: 7435-42.
36. Robey RB, Hay N., Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006; 25: 4683-96.
37. Jiang BH, Liu LZ., AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets 2008; 8: 19-26.
38. Pasciu V, Posadino AM, Cossu A, et al., Akt down regulation by flavin oxidase-induced ROS generation mediates dose-dependent endothelial cell damage elicited by natural antioxidants. Toxicol Sci 2010; 114: 101-12.
39. Hoeflich A, Reisinger R, Lahm H, et al., Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 2001; 61: 8601-10.
40. Rho O, Kim DJ, Kiguchi K, et al., Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog 2011; 50: 264-79.
41. Dunlap SM, Celestino J, Wang H, et al., Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci USA 2007; 104: 11736-41.
42. Mehrian-Shai R, Chen CD, Shi T, et al., Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA 2007; 104: 5563-8.
43. Fukushima T, Tezuka T, Shimomura T, et al., Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-Associated gene CD24. J Biol Chem 2007; 282: 18634-44.
44. Mireuta M, Darnel A, Pollak M., IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 2010; 28: 243-55.
45. Martin JL, Baxter RC., Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology 2007; 148: 2532-241.
46. Russo VC, Schütt BS, Andaloro E, et al., Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology 2005; 146: 4445-4455.
47. Mendes KN, Wang GK, Fuller GN, et al., JNK mediates insulin-like growth factor binding protein 2/integrin alpha5-dependent glioma cell migration. Int J Oncol 2010; 37: 143-153.
48. Han S, Li Z, Master LM, et al., Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway. Br J Cancer 2014; 111: 1400-1409.